

**PHARMEDIC PHARMACEUTICAL
MEDICINAL JOINT STOCK COMPANY**

No: **64/PMC-HĐQT**

*Re: Explanation of the variance in business
results for the Third Quarter of 2026
compared with the same period of the
previous year.*

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Ho Chi Minh City, October 15, 2026

**To:- STATE SECURITIES COMMISSION OF VIETNAM
- HANOI STOCK EXCHANGE**

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding information disclosure on the securities market.

Based on the business performance results for the third quarter of 2026 compared with those of the third quarter of 2025, Pharmedic Pharmaceutical Medicinal Joint Stock Company hereby explains the reasons for the variance in business results of more than 10% between the two reporting periods as follows:


In the third quarter of 2026, net revenue increased by 15.09% and profit after tax increased by 14.39% compared to the same period of the previous year. The primary reason was the Company's change in its business policy in 2026, including an increase in trade discounts offered to customers in order to boost sales volume and profit. Cost of goods sold increased by only 9.03%, lower than the growth rate of net revenue, resulting in a 23.48% increase in gross profit and an improvement in the gross profit margin from 41.92% to 44.97%. This was the key factor contributing to the increase in profit. In addition, interest income from term deposits declined significantly, decreasing by 90.52%, and interest expenses on short-term borrowings increased sharply by 496.29%. Selling expenses also increased by 49.28% as the Company stepped up spending on sales promotion activities in line with its new business policy.

We hereby certify that the information provided is true and accurate, and we assume full responsibility before the law for the contents of this disclosure.

Recipients:

- As stated above;
- Archived.

**LEGAL REPRESENTATIVE
GENERAL DIRECTOR**



LE VIET HUNG